Biotech Banter: FDA Delay, Clinical Trial News, and Tweet of the Week

The latest from The Motley Fool's biotech show "Biotech Banter."

Max Macaluso
Max Macaluso and Brian Orelli
Apr 10, 2014 at 10:04AM
Health Care

In this edition of Biotech Banter, Motley Fool contributor Brian Orelli and health care bureau chief Max Macaluso discuss an FDA delay for MannKind's Afrezza, clinical trial results from Amgen's T-VEC, up-and-coming biotech Agios, and the biotech "Tweet of the Week."